Therapeutic potential of compounds targeting SARS-CoV-2 helicase

Matthew T.J. Halma, Mark J.A. Wever, Sanne Abeln, Didier Roche, Gijs J.L. Wuite

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.
Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalFrontiers in Chemistry
Volume10
DOIs
Publication statusPublished - 6 Dec 2022
Externally publishedYes

Keywords

  • COVID-19
  • drug repurposing
  • helicase
  • natural products
  • nsp13
  • SARS-CoV-2
  • small-molecule inhibitors

Fingerprint

Dive into the research topics of 'Therapeutic potential of compounds targeting SARS-CoV-2 helicase'. Together they form a unique fingerprint.

Cite this